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In the present study, to synthesize quinolone-piperazine alkylated analogues, initially 3,4-difluoro nitro benzene is 
reduced to yield 3,4-difluorobenzenamine which is treated with diethyl ethoxymethyl enemalonate to yield diethyl 2-((3,4-
difluorophenylamino) methylene) malonate. This has been further cyclized to produce ethyl 6,7-difluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate which is treated with iodoethane to produce ethyl 1-ethyl-6,7-diifluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate. This is hydrolyzed and subsequent nucleophilic substitution with piperazine at 7th position 
gives quinolone-piperazine derivative. This is alkylated to yield 1-ethyl-6-fluoro-7-(4-alkylpiperazin-1-yl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid which is treated with ethanol to afford the desired ethyl 1-ethyl-6-fluoro-7-(4-
hexylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate derivatives. Based on the antimicrobial activity studies, 
hexyl analog 8a exhibits potent antimicrobial activity against Staphylococcus aureus MTCC 96, Bacillus subtilis MTCC 
121, Micrococcus luteus MTCC 2470 (MIC value 1.9µg/mL), with respect to other synthesized compounds and reference 
drug ciprofloxacin. 8b (heptyl analogue) and 8c (nonyl analogue) show significant activity with MIC value 3.9µg/mL. In the 
case of antifungal screening, 8a, 8b and 8c show significant antifungal activity against Candida albicans MTCC 3017with 
MIC value ranged from 3.9 to 7.8µg/mL. Compounds 8a (butyl) shows potent minimum bactericidal concentration activity 
with MIC value 3.9µg/mL against the tested strains. 
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Diseases caused by microbial pathogens posing a big 
challenge to health of public due to the extensive 
occurrence of drug resistance. Therefore, of late, 
researchers focused on addressing the issue of drug 
resistant microbes generated from the misuse and 
unlimited use of antimicrobial agents. To deal with 
this problem researcher need to investigate for new 
powerful antimicrobial agents by modifying the 
structure of well-known antimicrobial agents.  
Quinolones are the most important common 
frameworks present in a large variety of molecules 
with various pharmacological activities. Especially, 
quinolone antibacterial agents represent a fast-
growing group of antibiotics. Fluoroquinolones (FQs) 
are the important heterocyclic compounds belong  
to the class of quinolones showing a broad spectrum 
of biological activities against various bacteria, 
mycobacteria, and parasites1-9. Fluoroquinolones 
emerged as an important class of antibiotics  
for treating various bacterial infections namely, 
urinary tract, respiratory tract, gastrointestinal, 
abdominal, skin, soft tissue, bone and joints and 
further, it can be used to treat sexually transmitted 
diseases10.  
Various studies revealed that fluoroquinolone 
derivatives also showed the antiproliferative activities 
in some tumor cells such as breast cancer cells11, 
bladder transitional cell carcinoma12-14, non small cell 
lung carcinoma15, prostate carcinoma16, 17 and 
colorectal carcinoma18. The well known 
Fluoroquinolone derivative ciprofloxacin exhibited 
antiproliferative and apoptosis inducing activities both 
on prostate and bladder cancer cells11, 19, 16, 17. The 
suppression of DNA gyrase and cell permeability of 
fluoroquinolones is effectively influenced by 
substitution of a big functional group at the C-7 
position and greatly effects their antibacterial 
efficacy, spectrum and safety20, 21. In recent years a 
number of quinolone compounds with substitution of 
piperazine ring at C-7 position were synthesized and 
evaluated for antibacterial activities22-25. Generally, 
the action of fluoroquinolones increases with an 
increase in lipophilicity26. In addition, oils and fats are 
the most significant renewable raw materials for the 
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chemical industry. Fatty acids are aliphatic carboxylic 
acids produced from the cleavage of fats and oils 
regarded as non toxic, bio-compatible and bio-
degradable. These fatty acid derivatives are found to 
be associated with diverse types of biological 
activities, such as antimicrobial26, 27, antifungal28, 
anticancer29-31 and pesticidal32 activities. Hybrid 
molecules, in general designed based on taking two or 
more pharmacophores into a single molecule. The 
hybrid molecules with novelty are expected to exhibit 
optimal activities.  
Motivated by the above-mentioned findings and in 
continuation of our studies towards synthesis of 
carboxylated quinolones having alkyl chain moiety, 
herein we plan to synthesize a new class of 
carboxylated fluoroquinolones with the alkyl chain 
moiety on the piperazinyl ring by alkylation to 
generate hybrid molecules with potential biological 
activities. In the present study, a series of ethyl 1-
ethyl-6-fluoro-7-(4-alkylpiperazin-1-yl)-4-oxo-1,4-
dihydroquinoline-3-carboxylate derivatives were 
synthesized and evaluated for their biological 
activities.  
Results and Discussion 
The synthesis of targeted fluoroquinolones, ethyl 7-
(4-alkylpiperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1, 4-
dihydroquinoline-3-carboxylate is outlined in Scheme I. 
The starting material, 3,4-difluoro nitro benzene 
was reduced to yield 3,4-difluorobenzenamine by 
using iron and ammonium chloride in methanol and 
water. Resultant reduced 3,4-difluorobenzenamine 
was treated with diethyl ethoxymethyl enemalonate  
to yield diethyl 2-((3,4-difluorophenylamino) 
methylene)malonate. The intermediate ethyl 6,7-
difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
was achieved by the cyclization of diethyl 2-((3,4-
difluorophenylamino)methylene) malonate in 
presence of diphenyl ether. Ethyl 6,7-difluoro-4-oxo-
1,4-dihydroquinoline-3-carboxylate was treated with 
iodoethane in presence of K2CO3 and dry DMF  
to produce ethyl 1-ethyl-6,7-diifluoro-4-oxo-1,4- 
dihydroquinoline-3-carboxylate. This was hydrolyzed 
with 2N HCl and acetic acid followed by the 
nucleophilic substitution with piperazine at 7th 
position in the presence of triethyl amine to give 
respective quinolone-piperazine derivative.  
 
 
Scheme I — Reagents and conditions: (a) Fe, NH4Cl, H2O, MeOH, 90°C, 12 h; (b) Diethyl ethoxymethyl enemalonate, 120°C, 4 h; (c) 
Diphenyl ether, 255°C, 6 h; (d) K2CO3, C2H5-I, DMF, 85°C, 16 h; (e) (1) MeOH, 10% HCl, 80°C, 12 h; (2) Piperazine, Et3N, reflux for 
8 h; (f) Alkyl bromide, Et3N, DMF, 80-90°C, 2 h; (g) SOCl2, MeOH, reflux for 12 h 
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Further the quinolone piperazine derivative was 
alkylated by using various alkyl bromides in  
the presence of triethyl amine and DMF to yield  
1-ethyl-6-fluoro-7-(4-alkylpiperazin-1-yl)-4-oxo-1,4-
dihydroquinoline -3-carboxylic acid. Then this 
compound was reacted with thionyl chloride in 
presence of ethanol to yield the required ethyl  
1-ethyl-6-fluoro-7-(4-hexylpiperazin-1-yl)-4-oxo-1,4-
dihydroquinoline-3-carboxylate derivatives. The 
synthesized compounds were characterized by 
spectral data (1H NMR, 13C NMR, IR, and ESI-MS).  
 
Antimicrobial Activity 
All the newly synthesized compounds 8a–h were 
directly screened for in vitro antimicrobial, minimum 
bactericidal activity and biofilm inhibition activity 
against different gram-positive bacterial strains such 
as Staphylococcus aureus MTCC 96, Bacillus subtilis 
MTCC 121, S. aureus MLS16 MTCC 2940, 
Micrococcus luteus MTCC 2470, and gram-negative 
bacterial strains such as Klebsiella planticola MTCC 
530, Escherichia coli MTCC 739, Pseudomonas 
aeruginosa MTCC 2453 and fungi such as Candida 
albicans MTCC 3017. 
The antimicrobial activity results showed (Table I) 
that majority of the compounds exhibited either 
promising or significant activities. Compound 8a 
exhibited potent antimicrobial activity against 
Staphylococcus aureus MTCC 96, Bacillus subtilis 
MTCC 121, Micrococcus luteus MTCC 2470  
(MIC value 1.9µg/mL) and compounds 8a (against  
S. aureus MLS16 MTCC 2940 and Klebsiella 
planticola MTCC 530 strains), 8b (against 
Staphylococcus aureus MTCC 96, Bacillus subtilis 
MTCC 121, Micrococcus luteus MTCC 2470 strains), 
8c (against Staphylococcus aureus MTCC 96, 
Bacillus subtilis MTCC 121 and Pseudomonas 
aeruginosa MTCC 2453 strains) showed significant 
activity with MIC value 3.9µg/mL and remaining 
compounds showed good activity against various 
strains with MIC value ranged from 7.8 to 15.6 
µg/mL. In the case of antifungal screening, 8a, 8b, 
and 8c showed significant antifungal activity against 
Candida albicans MTCC 3017with MIC value ranged 
from 3.9 to7.8 µg/mL. The activity results in this 
regard are furnished in Table I. Compound 8a (hexyl) 
showed potent minimum bactericidal concentration 
activity against Staphylococcus aureus MTCC 96, 
Bacillus subtilis MTCC 121 and Micrococcus luteus 
MTCC 2470 (MIC value 3.9µg/mL). Compounds 8b 
(heptyl) against Staphylococcus aureus MTCC 96, 
Bacillus subtilis MTCC 121, Micrococcus luteus 
MTCC 2470 and Candida albicans MTCC 3017 
(MIC value 7.8µg/mL) and 8c (nonyl) against 
Staphylococcus aureus MTCC96, Bacillus subtilis 
MTCC 121 and Pseudomonas aeruginosa MTCC 
2453 (MIC value 7.8µg/mL) displayed promising 
activities. The activity results in this regard are 
furnished in Table II. 
It is noteworthy that compounds with short and 
medium chain fatty alkyl substituents on the 
piperazinyl ring exhibited potent activity. This is 
 
 
Table I — Antimicrobial activity of synthesized compounds 
Test compd Minimum inhibitory concentration (µg/mL) 
Staphylococcus 
aureus 
MTCC 96 
Bacillus 
subtilis 
MTCC 121 
S. aureus 
MLS16 
MTCC 
2940 
Micrococcus 
luteus 
MTCC 2470 
Klebsiella 
planticola 
MTCC 530 
Escherichia 
coli 
MTCC 739 
Pseudomonas 
aeruginosa 
MTCC 2453 
Candida  
albicans 
MTCC 3017 
8a 1.9 1.9 3.9 1.9 3.9 7.8 7.8 3.9 
8b 3.9 3.9 7.8 3.9 7.8 7.8 7.8 3.9 
8c 3.9 3.9 7.8 7.8 7.8 15.6 3.9 7.8 
8d 15.6 7.8 >125 15.6 >125 >125 7.8 >125 
8e >125 7.8 >125 15.6 >125 >125 15.6 >125 
8f >125 7.8 >125 15.6 >125 >125 15.6 >125 
8g >125 >125 >125 >125 >125 >125 15.6 >125 
8h >125 >125 >125 >125 >125 >125 15.6 >125 
Miconazole 
(Standard 
control) 
– – – – – – – 7.8 
Ciprofloxacin 
(Standard 
control) 
0.9 0.9 0.9 0.9 0.9 0.9 0.9 – 
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evident from compound 8a (hexyl analogue), 8b 
(heptyl analogue) and 8c (nonyl analogue) which are 
either short chain or medium chain analogues. The 
long chain compounds 8e (12 carbon chain), 8f  
(14 carbon chain), 8g (16 carbon chain) and 8h  
(18 carbon chain) were found to exhibit no significant 
activity. Based on the antimicrobial activities of the 
synthesized derivatives, all the compounds were 
screened for antibiofilm activity against 
Staphylococcus aureus MLS-16 MTCC 2940, 
Micrococcus luteus MTCC 2470, Klebsiella 
planticola MTCC 530, Pseudomonas aeruginosa 
MTCC 2453 and Candida albicans MTCC 
3017which are important nosocomial pathogens 
encountered in medical establishments and devices 
and have the ability to form biofilms. The results to 
this regard are summarized in Table III, which clearly 
reveal that these compounds exhibited moderate to 
low activities against all the tested strains. 
 
Experimental Section 
All the chemicals used in this study were of 
analytical grade and they were procured from various 
commercial sources and used without any further 
purification. Progress of reactions was monitored on 
micro TLC plates (coated with TLC grade silica gel, 
procured from Merck). Column chromatography was 
carried out by using silica gel (100-200 mesh) 
obtained from Qualigens (India) using freshly 
distilled solvents. 1H-NMR and 13C-NMR spectra 
were recorded using a Bruker Avance (for 1H-NMR at 
300 MHz, 400 MHz, 500 MHz and for 13C-NMR at 
75 MHz, 100 MHz, 125 MHz) spectrometer, using 
TMS for proton NMR (δ = 0 ppm) and δ 77.00 ppm 
 
Table II — Minimum bactericidal concentration (MBC) of synthesized compounds 
Test compd Minimum bactericidal concentration (µg/mL) 
Staphylococcu
s aureus 
MTCC 96 
Bacillus 
subtilis 
MTCC 121 
S. aureus 
MLS16 
MTCC 2940 
Micrococcus 
luteus 
MTCC 2470 
Klebsiella 
planticola 
MTCC 530 
Escherichia 
coli 
MTCC 739 
Pseudomonas 
aeruginosa 
MTCC 2453 
Candida albicans 
MTCC 3017 
8a 3.9 3.9 7.8 3.9 37.8 15.6 15.6 7.8 
8b 7.8 7.8 15.6 7.8 15.6 15.6 15.6 7.8 
8c 7.8 7.8 15.6 15.6 15.6 31.2 7.8 15.6 
8d 31.2 15.6 >125 31.2 15.6 >125 15.6 >125 
8e >125 15.6 >125 31.2 15.6 >125 31.2 >125 
8f >125 15.6 >125 31.2 15.6 >125 31.2 >125 
8g >125 >125 >125 >125 >125 >125 31.2 >125 
8h >125 >125 >125 >125 >125 >125 31.2 >125 
Miconazole 
(Standard 
control) 
– – – – – – – 7.8 
Ciprofloxacin 
(Standard 
control) 
0.9 0.9 0.9 0.9 0.9 0.9 0.9 – 
 
Table III — Biofilm activity of synthesized compounds 
Test compd IC50 values (µM) 
S. aureus MLS16 
MTCC 2940 
Micrococcus luteus 
MTCC 2470 
Klebsiella planticola 
MTCC 530 
Pseudomonas 
aeruginosa 
MTCC 2453 
Candida albicans 
MTCC 3017 
8a NA 31.4 ± 0.06 27.21 ± 0.12 48.7 ± 0.13 30.54 ± 0.12 
8b NA 44.94 ± 0.08 NA NA 112.35 ± 0.14 
8c NA 32.15 ± 0.07 NA 42.6 ± 0.09 41.8 ± 0.07 
8d NA 27.10 ± 0.09 NA NA NA 
8e 58.96 ± 0.08 29.12 ± 0.08 NA NA 38.83 ± 0.09 
8f NA 31.30 ± 0.08 NA NA 32.40 ± 0.016 
8g NA NA NA NA 35.02 ± 0.09 
Ciprofloxacin 0.7 ± 0.09 0.8 ± 0.11 0.8 ± 0.09 0.5 ± 0.12 – 
Miconazole – – – – 2.5 ± 0.09 
NA = No activity. 
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for13C-NMR as internal standard for chemical shifts 
(δ) in CDCl3 at 25°C. The chemical shift values are 
showed in ppm (parts per million) units. Infrared 
spectral analysis was carried out in chloroform 
solvent on a Perkin-Elmer FT-IR spectrum BX. Using 
High Resolution Mass Spectrometry (HRMS) mass 
spectral data was recorded.  
 
3,4-Difluoroaniline, 2: 1,2-difluoro-4-nitrobenzene 
(4 g, 1 mmol) was taken in methanol and water  
(25 mL: 5 mL) at rt and stirred, to this stirred solution 
iron powder (2.5 g) and ammonium chloride (2 g) 
were added. This stirred solution was then refluxed 
for 12 h and the progress of reaction was monitored 
by TLC. After 12 h reaction period the reaction 
mixture was filtered with the aid of celite pad. Then 
the solvent was removed under reduced pressure, 
water was added and the product was extracted using 
ethyl acetate solvent and dried over anhydrous sodium 
sulphate. Silica gel column chromatography was 
employed to purify crude product and the required 
product was eluted in a solvent mixture (Hexane: 
EtOAc, 30: 70, v/v) as a brown liquid with 77% yield. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.88-6.94 (m, 
1H, Ar-H), 6.43-6.47 (m, 1H, Ar-H), 6.31-6.34 (m, 
1H, Ar-H), 3.60 (s, 2H, NH2); 13C-NMR (125 MHz, 
CDCl3): δ (ppm) = 150.8, 147.6, 143.3, 140.0, 115.8, 
108.5, 101.8; IR (CHCl3 νmax cm-1): 3383, 2360, 1617, 
1521, 1266, 1213; MS (ESI, m/z) [M+H]+ 130. 
 
Diethyl 2-((3,4-difluorophenylamino) methylene) 
malonate, 3: A mixture of 3,4-difluoroaniline  
(2.5 g, 1 mmol), diethyl [(ethyloxy) methylidene] 
propanedioate (2.5 g, 1 mmol) was heated at 120°C 
for 4 h. The reaction mixture was cooled to room 
temperature and reduced to dryness in vacuum to 
obtain the desired diethyl 2-((3,4-difluorophenylamino) 
methylene) malonate. The product so obtained was 
used for the next step without further purification.  
IR (CHCl3 νmax cm-1): 3442, 2361, 1635, 1225, 1080, 
800; HRMS (ESI) m/z[M+H+]- calc for C14H16F2NO4 
is 300.10419 found 300.10425 (C14H16F2NO4). 
 
Ethyl 6,7-difluoro-4-oxo-1,4-dihydroquinoline-
3-carboxylate, 4: Small portions of 2-((3,4-
difluorophenylamino) methylene) malonate (4 g, 1 
mmol) was added to boiling diphenyl ether (30 mL) 
over a period of 10 min at about 255°C and the 
contents were heated for 6 h. Then the reaction 
mixture was cooled to 50°C and diethyl ether was 
added to dilute it and cooled further to obtain a 
precipitate. Then filtration was carried out to collect 
the solid residue and this was washed with diethyl 
ether and dried in vacuum to get ethyl 6,7-difluoro-4-
oxo-1,4-dihydroquinoline-3-carboxylate. The attained 
title compound (1.8 g, 53% yield, white solid) was 
used in the next reaction step without further 
purification. IR (CHCl3 νmax cm-1):3441, 2360, 1678, 
759; MS (ESI, m/z) [M+H]+ 254. 
 
Ethyl1-ethyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline 
-3-carboxylate, 5: DMF (20 mL) was used to dissolve 
Ethyl-6, 7-difluoro-4-oxo-1, 4-dihydroquinoline-3-
carboxylate (2 g, 1 mmol). Potassium carbonate  
(3.5 g, 1.5 mmol) and iodoethane (2 mL, 1 mmol) 
were added consecutively to this solution and the 
contents were magnetically stirred at 85 °C for 16 h. 
Micro TLC with UV detection was used to monitor 
the progress of reaction. At the end of reaction, water 
was added and ethyl acetate was used to extract the 
title compound, dried using anhydrous sodium 
sulphate. Silica gel column chromatography was 
employed to purify the crude product and ethyl acetate 
was used to elute the required product as a light yellow 
solid with 63% yield. 1H-NMR (300 MHz, CDCl3):  
δ (ppm) = 8.49 (s, 1H, Ar-H), 8.28 –8.32 (m, 1H,  
Ar-H), 7.26 - 7.29 (m, 1H, Ar-H), 4.37 – 4.42 (m,  
2H, CH2), 4.19 - 4.23 (m, 2H, CH2), 1.54 – 1.57  
(t, J = 7.2 Hz, 3H, CH3), 1.40 – 1.42 (t, J = 6.9 Hz, 
3H, CH3); 13C-NMR (75 MHz, CDCl3) δ (ppm) 
=171.0, 163.2, 153.4, 150.0, 145.1, 134.3, 124.8, 113.6, 
109.1, 104.0, 59.1, 47.8, 13.0; IR (CHCl3 νmax cm-1): 
3684, 3020, 2400, 2130, 1616, 1473, 1215, 1025, 762, 
669; HRMS (ESI) m/z [M+Na+]: calc for 
C14H13F2NO3Na is 304.07557 found 304.07538 
(C14H13F2NO3Na).  
 
1-Ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylic acid, 6: 10% HCl (2 
mL) was added to the stirred solution of Ethyl- 
1-ethyl-6, 7-difluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (55mg, 0.020 mmol) in methanol (2mL) 
and the contents were heated at 80°C for 12 h. After 
12 h period, the mixture was cooled and water (2 mL) 
was added, the solid precipitate was filtered and dried 
to obtain the carboxylic acid (49 mg) compound. This 
acid was suspended in water (2 mL), to this solution 
triethyl amine (0.075 mL, 0.5 mmol), piperazine  
(47 mg, 0.5 mmol) were added consecutively the 
mixture was refluxed for 8 h period. Precipitation was 
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obtained after the reaction mixture was cooled and 
treated with acetic acid. Subsequently, filtered to get 
the precipitate and this was water washed and dried to 
obtain norfloxacin (55mg, 84% yield). MS (ESI, m/z) 
[M+H]+ 320.  
 
General Procedure for the Synthesis of Target 
Compounds, 7a-h: The contents 1-Ethyl-6- 
fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-
carboxylic acid (2 g, 1 mmol), triethylamine (1.5 g, 
0.015 mol) and alkyl bromide (0.012-0.02 mol) in 
DMF solvent (40 mL) were heated at 80-90°C 
temperature for 2 h period under magnetic stirring. 
The progression in reaction was supervised by TLC 
under UV detection. After conformation with TLC, 
solvent present in the reaction mixture was evaporated 
to dryness. The suspension was made using residue 
and water and the solid obtained was filtered and 
dried to get the unpurified 1-ethyl-6-fluoro-7- 
(4-alkylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-
carboxylic acid products. Silica gel-based column 
chromatography was employed to purify the crude 
compound and the required product was eluted as a 
white solid in chloroform, methanol, (99: 1, v/v) 
solvent mixture.  
 
1-Ethyl-6-fluoro-7-(4-hexylpiperazin-1-yl)-4-oxo- 
1,4-dihydroquinoline-3-carboxylic acid, 7a: The 
crude compound was subjected to silica gel column 
chromatography and the required product was eluted 
in a solvent mixture (Chloroform: Methanol, 99:  
1, v/v) as a white solid with 79% yield. 1H NMR  
(500 MHz, CDCl3): δ (ppm) = 15.14 (s, 1H, COOH), 
8.67 (s, 1H, Ar-H), 8.05 (d, J = 13.12 Hz, 1H, Ar-H), 
6.84 (d, J = 6.86 Hz, 1H, Ar-H), 4.36-4.32 (m, 2H,  
N-CH2), 3.35 (broad-s, 4H, 2HC-N-CH2), 2.67 (broad-s, 
4H, 2HC-N-CH2), 2.44-2.41 (t, J = 7.47Hz, 2H, CH2), 
1.60-1.53 (m, 5H, CH2, CH3), 1.39-1.29 (m, 6H, 
(CH2)3,), 0.90-0.88 (t, J = 6.56Hz, 3H, CH3); 13C 
NMR (125 MHz, CDCl3): δ (ppm) = 176, 167, 154, 
146, 145, 137, 120, 112, 107, 103, 58, 57, 53, 52, 49, 
49, 31, 28, 27, 26, 22, 22, 14, 13; IR (CHCl3 νmax cm-1): 
3424, 2929, 2856, 1718, 1626, 1584, 1490, 1382, 
1220, 771.  
 
1-Ethyl-6-fluoro-7-(4-heptylpiperazin-1-yl)-4-oxo- 
1,4-dihydroquinoline-3-carboxylic acid, 7b: The 
crude compound was subjected to silica gel column 
chromatography and the required product was eluted 
in a solvent mixture (Chloroform: Methanol, 99:  
1, v/v) as a white solid with 73% yield. 1H NMR  
(400 MHz, CDCl3): δ (ppm) = 15.10 (s, 1H, COOH), 
8.67 (s, 1H, Ar-H), 8.06 (d, J = 13.12 Hz, 1H, Ar-H), 
6.83 (d, J = 6.71 Hz, 1H, Ar-H), 4.34-4.30 (m, 2H,  
N-CH2), 3.34 (broad-s, 4H, 2HC-N-CH2), 2.67 (broad-s, 
4H, 2HC-N-CH2), 2.43-2.40 (t, J = 7.47Hz, 2H, CH2), 
1.62-1.50 (m, 5H, CH2, CH3), 1.31-1.27 (m, 8H, 
(CH2)4,), 0.89-0.87 (t, J = 6.86Hz, 3H, CH3);  
13C NMR (100 MHz, CDCl3): δ (ppm) = 176.9,  
167.2, 154.7, 147.0, 146.2, 137.0, 120.4, 112.8, 108.3, 
103.6, 58.6, 52.8, 49.8, 49.7, 31.8, 29.5, 29.2, 27.4, 
26.8, 22.6, 14.3, 14.0; IR (CHCl3 νmax cm-1): 3424, 
2929, 2856, 1717, 1626, 1546, 1490, 1382, 1220, 
1089, 771. 
 
1-Ethyl-6-fluoro-7-(4-nonylpiperazin-1-yl)-4-oxo- 
1,4-dihydroquinoline-3-carboxylic acid, 7c: The 
crude compound was subjected to silica gel column 
chromatography and the required product was eluted 
in a solvent mixture (Chloroform: Methanol, 99:  
1, v/v) as a white solid with 85% yield. 1H NMR  
(500 MHz, CDCl3): δ (ppm) = 15.12 (s, 1H, COOH), 
8.66 (s, 1H, Ar-H), 8.03 (d, J = 13.08 Hz, 1H, Ar-H), 
6.84 (d, J = 6.96 Hz, 1H, Ar-H), 4.36-4.31 (m, 2H,  
N-CH2), 3.35 (broad-s, 4H, 2HC-N-CH2), 2.67 (broad-s, 
4H, 2HC-N-CH2), 2.44-2.40 (t, J = 7.58Hz, 2H, CH2), 
1.60-1.51 (m, 5H, CH2, CH3), 1.41-1.28 (m, 12H, 
(CH2)6,), 0.90-0.87 (t, J = 6.72Hz, 3H, CH3); 13C 
NMR (100 MHz, CDCl3): δ (ppm) = 176.7, 167.1, 
154.6, 146.9, 146.1, 137.0, 120.1, 112.4, 108.0, 103.6, 
58.5, 53.4, 52.7, 49.7, 31.7, 29.4, 29.1, 27.4, 26.6, 
22.5, 14.3, 13.9; IR (CHCl3 νmax cm-1): 3424, 2929, 
2856, 1719, 1626, 1584, 1490, 1220, 771.  
 
7-(4-Decylpiperazin-1-yl)-1-ethyl-6-fluoro-4-oxo- 
1,4-dihydroquinoline-3-carboxylic acid, 7d: The 
crude compound was subjected to silica gel column 
chromatography and the required product was eluted 
in a solvent mixture (Chloroform: Methanol, 99:  
1, v/v) as a white solid with 80% yield. 1H NMR  
(500 MHz, CDCl3): δ (ppm) = 15.11(s, 1H, COOH), 
8.67 (s, 1H, Ar-H), 8.06 (d, J = 13.08 Hz, 1H, Ar-H), 
6.83 (d, J = 6.96 Hz, 1H, Ar-H), 4.35-4.29 (m, 2H,  
N-CH2), 3.34 (t, J = 4.76 Hz, 4H, 2HC-N-CH2), 2.67 
(t, J = 4.89 Hz, 4H, 2HC-N-CH2), 2.44-2.40 (t,  
J = 7.58Hz, 2H, CH2), 1.60-1.49 (m, 5H, CH2, CH3), 
1.39-1.31 (m, 14H, (CH2)7,), 0.91-0.88 (t, J = 6.48Hz, 
3H, CH3); 13C NMR (125 MHz, CDCl3): δ (ppm) = 
176.9, 167.1, 154.7, 147.0, 146.1, 137., 120.3, 112.7, 
108.2, 103.6, 58.5, 52.7, 49.8, 49.7, 31.7, 27.1, 26.7, 
22.5, 14.3, 14.0; IR (CHCl3 νmax cm-1): 3424, 2929, 
2856, 1719, 1626, 1584, 1490, 1220, 771.  
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7-(4-Dodecylpiperazin-1-yl)-1-ethyl-6-fluoro-4-oxo- 
1,4-dihydroquinoline-3-carboxylic acid, 7e: The 
crude compound was subjected to silica gel column 
chromatography and the required product was eluted 
in a solvent mixture (Chloroform: Methanol, 99:  
1, v/v) as a white solid with 74% yield. 1H NMR  
(500 MHz, CDCl3): δ (ppm) = 15.10(s, 1H, COOH), 
8.67 (s, 1H, Ar-H), 8.06 (d, J = 13.12 Hz, 1H, Ar-H), 
6.83 (d, J = 6.86 Hz, 1H, Ar-H), 4.34-4.29 (m, 2H,  
N-CH2), 3.35-3.33 (t, J = 4.57 Hz, 4H, 2HC-N-CH2), 
2.67-2.66 (t, J = 4.88 Hz, 4H, 2HC-N-CH2), 2.43-2.40 
(t, J = 7.62Hz, 2H, CH2), 1.61-1.50 (m, 5H, CH2, 
CH3), 1.32-1.26 (m, 18H, (CH2)9,), 0.89-0.86 (t,  
J = 6.86Hz, 3H, CH3); 13C NMR (125 MHz, CDCl3): 
δ (ppm) = 176.8, 167.1, 154.7, 146.9, 146.1, 137.0, 
120.3, 112.7, 108.2, 103.6, 58.6, 52.8, 49.8, 31.8, 29.6, 
29.3, 27.4, 26.8, 22.6, 14.3, 14.0; IR (CHCl3 νmax cm-1): 
3431, 2919, 2850, 1721, 1620, 1504, 1462, 1382, 
1219, 1089, 768.  
 
1-Ethyl-6-fluoro-4-oxo-7-(4-tetradecylpiperazin-
1-yl)-1,4-dihydroquinoline-3-carboxylic acid, 7f: 
The crude compound was subjected to silica gel 
column chromatography and the required product was 
eluted in a solvent mixture (Chloroform: Methanol, 
99: 1, v/v) as a white solid with 79% yield. 1H NMR 
(400 MHz, CDCl3): δ (ppm) = 15.11 (s, 1H, COOH), 
8.67 (s, 1H, Ar-H), 8.06 (d, J = 13.08 Hz, 1H, Ar-H), 
6.83 (d, J = 6.96 Hz, 1H, Ar-H), 4.35-4.30 (m, 2H,  
N-CH2), 3.36-3.34 (t, J = 4.76 Hz, 4H, 2HC-N-CH2), 
2.69-2.66 (t, J = 4.89 Hz, 4H, 2HC-N-CH2), 2.45-2.41 
(t, J = 7.58Hz, 2H, CH2), 1.61-1.50 (m, 5H, CH2, 
CH3), 1.32-1.27 (m, 22H, (CH2)11,), 0.90-0.87 (t,  
J = 6.72Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3):  
δ (ppm) = 176.8, 167.1, 154.7, 147.0, 146.1, 137.0, 
120.3, 112.75, 108.2, 103.6, 58.5, 52.8, 49.8, 49.7, 
31.8, 29.6, 29.3, 27.4, 26.7, 22.6, 14.3, 14.0; IR 
(CHCl3 νmax cm-1): 3430, 2918, 2850, 1721, 1620, 
1582, 1492, 1382, 1220, 1089, 771.  
 
1-Ethyl-6-fluoro-7-(4-hexadecylpiperazin-1-yl)-4- 
oxo-1,4-dihydroquinoline-3-carboxylic acid, 7g: 
The crude compound was subjected to silica gel 
column chromatography and the required product was 
eluted in a solvent mixture (Chloroform: Methanol, 
99: 1, v/v) as a white solid with 78% yield. 1H NMR 
(500 MHz, CDCl3): δ (ppm) = 15.11 (s, 1H, COOH), 
8.67 (s, 1H, Ar-H), 8.05 (d, J = 13.20 Hz, 1H, Ar-H), 
6.83 (d, J = 6.05 Hz, 1H, Ar-H), 4.38-4.24 (m, 2H,  
N-CH2), 3.36-3.34 (t, J = 4.76 Hz, 4H, 2HC-N-CH2), 
2.69-2.66 (t, J = 4.89 Hz, 4H, 2HC-N-CH2), 2.44-
2.39(t, J = 7.42Hz, 2H, CH2), 1.70-1.53 (m, 5H, CH2, 
CH3), 1.39-1.25 (m, 26H, (CH2)13,), 0.90-0.85 (t,  
J= 6.05Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3):  
δ (ppm) = 176.9, 167.1, 154.7, 146.9, 146.1, 137.0, 
120.3, 112.7, 108.2, 103.6, 58.6, 52.8, 49.8, 49.8, 
49.7, 31.8, 29.5, 29.3, 27.4, 26.8, 22.6, 14.3, 14.0;  
IR (CHCl3 νmax cm-1): 3428, 2917, 2849, 1721, 1620, 
1504, 1462, 1383, 1221, 1089, 771.  
 
1-Ethyl-6-fluoro-7-(4-octadecylpiperazin-1-yl)-4- 
oxo-1,4-dihydroquinoline-3-carboxylic acid, 7h: 
The crude compound was subjected to silica gel 
column chromatography and the required product was 
eluted in a solvent mixture (Chloroform: Methanol, 
99: 1, v/v) as a white solid with 83% yield. 1H NMR 
(500 MHz, CDCl3): δ (ppm) = 15.11 (s, 1H, COOH), 
8.67 (s, 1H, Ar-H), 8.06 (d, J = 13.08 Hz, 1H, Ar-H), 
6.83 (d, J = 6.96 Hz, 1H, Ar-H), 4.35-4.30 (m, 2H,  
N-CH2), 3.36-3.34 (t, J = 4.76 Hz, 4H, 2HC-N-CH2), 
2.69-2.66 (t, J = 4.89 Hz, 4H, 2HC-N-CH2), 2.45-2.41 
(t, J = 7.58Hz, 2H, CH2), 1.61-1.50 (m, 5H, CH2, 
CH3), 1.32-1.27 (m, 30H, (CH2)15), 0.90-0.87 (t,  
J = 6.67Hz, 3H, CH3); 13C NMR (125 MHz, CDCl3): 
δ (ppm) = 176.9, 167.2, 154.5, 147.0, 146.0, 137.0, 
120.4, 112.7, 108.2, 103.6, 58.5, 52.7, 49.7, 36.4, 
31.8, 31.4, 29.6, 29.3, 27.4, 26.7, 22.6, 14.3, 14.0; IR 
(CHCl3 νmax cm-1): 3428, 2917, 2849, 1721, 1620, 
1504, 1462, 1383, 1221, 1089, 771. 
 
General Procedure for the Synthesis of Target 
Compounds, 8a-h: 1-Ethyl-6-fluoro-7-(4-
alkylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3- 
carboxylic acid(2 g, 1 mmol) was taken in methanol 
(20 mL) and slowly SOCl2 (3.5 g, 1.5 mmol) was 
added and the contents were refluxed under stirring 
for 12 h period. The reaction progression was 
monitored by micro TLC with UV detection. The 
solvent was removed under rotary evaporation after 
the 12 h reaction period. The title compound was 
extracted with ethyl acetate and water washings  
given and dried over anhydrous sodium sulphate.  
This crude compound was purified by silica gel 
column chromatography and the required product was 
eluted as an off white solid in hexane, ethyl acetate 
(20: 80, v/v) solvent mixture.  
 
Ethyl 1-ethyl-6-fluoro-7-(4-hexylpiperazin-1-yl)-
4-oxo-1,4-dihydroquinoline-3-carboxylate, 8a: The 
crude compound was purify employing silica gel-
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based column chromatography and the desired 
product was eluted in hexane, ethyl acetate mixture 
(20: 80, v/v) as an off white solid in 63% yield. 1H 
NMR (500 MHz, CDCl3): δ (ppm) = 8.41(s, 1H,  
Ar-H), 8.10(d, J = 13.27 Hz, 1H, Ar-H), 6.74 (d,  
J = 6.40 Hz, 1H, Ar-H), 4.37-4.41 (m, 2H, N-CH2), 
4.19-4.20 (m, 2H, OCH2), 3.27 (broad-s, 4H, 2HC-N-
CH2), 2.66 (broad-s, 4H, 2HC-N-CH2), 2.41-2.44 (t,  
J = 7.47Hz, 2H, CH2), 1.52-1.54 (m, 5H, CH2, CH3), 
1.39-1.42 (t, J = 7.17Hz, 3H, CH3), 1.31-1.34 (m, 6H, 
(CH2)3), 0.88-0.1 (t, J = 6.56Hz, 3H, CH3); 13C NMR 
(125 MHz, CDCl3): δ (ppm) = 173.0, 165.8, 154.1, 
147.9, 144.7, 136.0, 123.7, 113.6, 110.4, 103.6, 60.7, 
58.6, 52.8, 49.9, 48.9, 31.7, 27.1, 26.6, 22.5, 14.3, 
14.3, 14.00; IR (CHCl3 νmax cm-1): 3692, 3423, 2925, 
2857, 1742, 1626, 1479, 1444, 1360, 1256, 753; 
HRMS (ESI) m/z [M+H+]: calc for C24H35O3N3F is 
432.26570 found 432.26466 (C24H35O3N3F). 
 
Ethyl 1-ethyl-6-fluoro-7-(4-heptylpiperazin-1-
yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, 8b: 
The crude compound was purified by silica gel-based 
column chromatography and the desired product was 
eluted in a solvent mixture of hexane and ethyl acetate 
(20: 80, v/v) as an off white solid with 65% yield. 1H 
NMR (500 MHz, CDCl3): δ (ppm) = 8.42 (s, 1H,  
Ar-H), 8.10 (d, J = 13.42 Hz, 1H, Ar-H), 6.75 (d,  
J = 6.71 Hz, 1H, Ar-H), 4.37-4.41 (m, 2H, N-CH2), 
4.17-4.22 (m, 2H, OCH2), 3.32 (broad-s, 4H, 2HC-N-
CH2), 2.73 (broad-s, 4H, 2HC-N-CH2), 2.47-2.49 (t,  
J = 6.56Hz, 2H, CH2), 1.52-1.60 (m, 5H, CH2, CH3), 
1.39-1.42 (t, J = 7.17Hz, 3H, CH3), 1.25-1.34 (m, 8H, 
(CH2)4), 0.87-0.90 (t, J = 6.86Hz, 3H, CH3); 13C NMR 
(100 MHz, CDCl3): δ (ppm) = 172.9, 165.4, 154.1, 
147.7, 144.4, 135.8, 123.4, 113.3, 110.0, 103.7, 60.5, 
58.4, 52.6, 49.5, 48.9, 31.6, 29.0, 27.2, 26.3, 22.4, 
14.3, 14.2, 13.9; IR (CHCl3 νmax cm-1): 3423, 2925, 
2857, 1742, 1615, 1479, 1444, 1360, 1256, 753; 
HRMS (ESI) m/z [M+H+]: calc for C23H38O3N3FNa is 
446.27894 found 446.28041 (C23H38O3N3FNa).  
 
Ethyl 1-ethyl-6-fluoro-7-(4-nonylpiperazin-1-yl)-
4-oxo-1,4-dihydroquinoline-3- carboxylate, 8c: The 
crude compound was purified by silica gel-based 
column chromatography and the required product (off 
white solid) was eluted from the column using a 
solvent mixture (Hexane: EtOAc, 20: 80, v/v) with 
68% yield. 1H NMR (500 MHz, CDCl3): δ (ppm) = 
8.43 (s, 1H, Ar-H), 8.03 (d, J = 12.66 Hz, 1H, Ar-H), 
6.83 (d, J = 6.56 Hz, 1H, Ar-H), 4.36-4.40 (m, 2H,  
N-CH2), 4.19-4.23(m, 2H, OCH2), 3.66 (broad-s, 4H, 
2HC-N-CH2), 3.33 (broad-s, 4H, 2HC-N-CH2), 2.99-
3.02(t, J = 7.01Hz, 2H, CH2), 1.89-1.92 (m, 5H, CH2, 
CH3), 1.53-1.56 (t, J = 7.17Hz, 3H, CH3), 1.26-1.42 
(m, 12H, (CH2)6), 0.87-0.90 (t, J = 6.71Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3): δ (ppm) = 172.8, 164.9, 
153.6, 151.6, 147.9, 142.9, 135.8, 124.3, 113.2, 110.1, 
105.0, 60.6, 57.4, 51.5, 49.0, 46.8, 31.6, 29.2, 29.0, 28.9, 
26.7, 23.7, 22.5, 14.4, 14.3, 13.9; IR (CHCl3 νmax cm-1): 
3424, 2925, 2857, 1742, 1615, 1479, 1444, 1360, 
1215, 754; HRMS (ESI) m/z [M+H+]: calc for 
C27H41O3N3F is 474.31265 found 474.31150 
(C27H41O3N3F).  
 
Ethyl 7-(4-decylpiperazin-1-yl)-1-ethyl-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylate, 8d: The 
crude compound was subjected to silica gel column 
chromatography and the targeted product (off white 
solid) was eluted in a hexane and ethyl acetate (20: 
80, v/v) solvent mixture with 65% yield. 1H NMR 
(400 MHz, CDCl3): δ (ppm) = 8.41 (s, 1H,  
Ar-H), 8.10 (d, J = 13.32 Hz, 1H, Ar-H), 6.74 (d,  
J = 5.25Hz, 1H, Ar-H), 4.41-4.36 (m, 2H, N-CH2), 
4.19-4.20 (m, 2H, OCH2), 3.28 (broad-s, 4H, 2HC-N-
CH2), 2.68 (broad-s, 4H, 2HC-N-CH2), 2.41-2.45 (t,  
J = 7.33Hz, 2H, CH2), 1.51-1.53 (m, 5H, CH2, CH3), 
1.39-1.42(t, J = 7.09Hz, 3H, CH3), 1.27-1.32 (m, 14H, 
(CH2)7), 0.86-0.90 (t, J = 6.48Hz, 3H, CH3); 13C NMR 
(100 MHz, CDCl3): δ (ppm) = 172.9, 165.7, 154.3, 
147.8, 144.5, 135.9, 123.6, 113.5, 110.3, 103.7, 60.7, 
58.5, 52.8, 49.7, 48.9, 31.8, 29.4, 29.2, 27.4, 26.6, 
22.6, 14.3, 14.2, 14.0; IR (CHCl3 νmax cm-1): 3423, 
2924, 2857, 1742, 1615, 1479, 1444, 1360, 1255, 753; 
HRMS (ESI) m/z [M+H+]: 488.32718.  
 
Ethyl 7-(4-dodecylpiperazin-1-yl)-1-ethyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 8e: 
The crude compound purified using silica gel column 
chromatography and the targeted product was eluted 
in a solvent mixture (Hexane: EtOAc, 20: 80, v/v) as 
an off white solid with 70% yield. 1H NMR (400 
MHz, CDCl3): δ (ppm) = 8.41 (s, 1H, Ar-H), 8.10 (d, 
J = 13.32 Hz, 1H, Ar-H), 6.74 (d, J = 6.84Hz, 1H,  
Ar-H), 4.36-4.41 (m, 2H, N-CH2), 4.17-4.22 (m, 2H, 
OCH2), 3.28 (broad-s, 4H, 2HC-N-CH2), 2.67 (broad-s, 
4H, 2HC-N-CH2), 2.40-2.44 (t, J = 7.45Hz, 2H, CH2), 
1.51-1.60 (m, 5H, CH2, CH3), 1.39-1.42 (t,  
J = 7.09Hz, 3H, CH3), 1.26-1.32 (m, 18H, (CH2)9), 
0.86-0.89 (t, J = 6.60Hz, 3H, CH3); 13C NMR (125 
MHz, CDCl3): δ (ppm) = 172.9, 165.7, 154.0, 147.8, 
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144.7, 135.9, 123.6, 113.5, 110.3, 103.6, 60.7, 58.6, 
52.8, 52.7, 49.8, 48.9, 31.8, 29.5, 29.2, 27.4, 26.6, 
22.6, 14.3, 14.2, 14.0; IR (CHCl3 νmax cm-1): 3019, 
2914, 2851, 1743, 1614, 1475, 1444, 1361, 1214, 757; 
HRMS (ESI) m/z [M+H+]: calc for C30H47O3N3F is 
516.35960 found 516.35866 (C27H41O3N3F).  
 
Ethyl 1-ethyl-6-fluoro-4-oxo-7-(4-tetradecylpiperazin 
-1-yl)-1,4-dihydroquinoline-3 carboxylate, 8f: The 
crude compound was subjected to silica gel column 
chromatography and the required off white (solid) 
coloured product was eluted in a solvent mixture of 
hexane and ethyl acetate (20: 80, v/v) with 78% yield. 
1H NMR (400 MHz, CDCl3):  
δ (ppm) = 8.43(s, 1H, Ar-H), 8.04 (d, J = 12.83 Hz, 
1H, Ar-H), 6.82 (d, J = 6.72Hz, 1H, Ar-H), 4.35-4.41 
(m, 2H, N-CH2), 4.18-4.23 (m, 2H, OCH2), 3.66 
(broad-s, 4H, 2HC-N-CH2), 3.31 (broad-s, 4H, 2HC-
N-CH2), 2.97-3.01 (t, J = 6.96Hz, 2H, CH2), 1.88-1.91 
(m, 5H, CH2, CH3), 1.52-1.56 (t, J = 7.21Hz, 3H, 
CH3), 1.26-1.42 (m, 22H, (CH2)11), 0.86-0.90 (t,  
J = 6.72Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): 
δ (ppm) = 172.8, 165.0, 153.8, 147.9, 143.0, 135.8, 
124.3, 113.4, 110.2, 104.9, 60.6, 57.5, 51.5, 49.0, 
46.9, 31.8, 29.5, 29.2, 28.9, 26.7, 23.7, 22.5, 14.4, 
14.3, 14.0; IR (CHCl3 νmax cm-1): 3019, 2914, 2851, 
1744, 1614, 1479, 1444, 1361, 1288, 771; HRMS 
(ESI) m/z [M+H+]: calc for C32H51O3N3F is 544.39090 
found 544.39042 (C32H51O3N3F).  
 
Ethyl 1-ethyl-6-fluoro-7-(4-hexadecylpiperazin-
1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, 8g: 
The crude compound was subjected to silica gel 
column chromatography and the chosen product (off 
white solid) was obtained in a hexane, ethyl acetate 
(20: 80, v/v) solvent mixture in 73% yield. 1H NMR 
(400 MHz, CDCl3): δ (ppm) = 8.41 (s, 1H, Ar-H), 
8.10 (d, J = 13.32 Hz, 1H, Ar-H), 6.74 (d, J = 6.84Hz, 
1H, Ar-H), 4.36-4.41 (m, 2H, N-CH2), 4.16-4.21 (m, 
2H, OCH2), 3.27 (broad-s, 4H, 2HC-N-CH2), 2.66 
(broad-s, 4H, 2HC-N-CH2), 2.40-2.44 (t, J = 7.45Hz, 
2H, CH2), 1.51-1.59 (m, 5H, CH2, CH3), 1.38-1.42 (t, 
J = 7.09Hz, 3H, CH3), 1.26-1.31 (m, 26H, (CH2)13), 
0.85-0.89 (t, J = 6.60Hz, 3H, CH3); 13C NMR (125 
MHz, CDCl3): δ (ppm) = 172.9, 165.3, 153.9, 147.8, 
144.1, 135.9, 123.7, 113.4, 110.1, 104.1, 60.6, 58.2, 
52.4, 48.9, 31.8, 29.5, 29.4, 29.3, 29.2, 27.2, 25.6, 
22.5, 14.3, 14.3, 14.0; IR (CHCl3 νmax cm-1): 3424, 
2913, 2850, 1743, 1614, 1479, 1443, 1380, 1219, 772; 
HRMS (ESI) m/z [M+H+]: calc for C34H55O3N3F is 
572.42220 found 572.42177 (C34H55O3N3F).  
Ethyl 1-ethyl-6-fluoro-7-(4-octadecylpiperazin-
1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, 
8h: Silica gel column chromatography of crude 
compound was performed and the aimed product was 
eluted in a hexane and ethyl acetate solvent mixture 
(20: 80, v/v) as an off white solid (60% yield). 1H 
NMR (400 MHz, CDCl3): δ (ppm) = 8.42 (s, 1H,  
Ar-H), 8.10 (d, J = 13.32 Hz, 1H, Ar-H), 6.75 (d,  
J = 6.72 Hz, 1H, Ar-H), 4.36-4.41 (m, 2H, N-CH2), 
4.17-4.22 (m, 2H, OCH2), 3.33 (broad-s, 4H, 2HC-N-
CH2), 2.74 (broad-s, 4H, 2HC-N-CH2), 2.48-2.51 (t,  
J = 6.72Hz, 2H, CH2), 1.51-1.60 (m, 5H, CH2, CH3), 
1.39-1.42 (t, J = 7.09Hz, 3H, CH3), 1.25-1.32 (m, 
30H, (CH2)15), 0.86-0.89 (t, J = 6.60Hz, 3H, CH3); 13C 
NMR (100 MHz, CDCl3): δ (ppm) = 173.0, 165.6, 
154.3, 147.8, 144.5, 135.9, 123.7, 113.5, 110.2, 103.8, 
60.7, 58.4, 52.7, 49.5, 48.9, 31.8, 29.6, 29.2, 27.3, 
26.3, 22.60, 14.3, 14.3, 14.0; IR (CHCl3 νmax cm-1): 
3442, 2913, 2850, 1744, 1614, 1479, 1443, 1380, 
1219, 772; HRMS (ESI) m/z [M+H+]: calc for 
C36H59O3N3F is 600.45350 found 600.45363 
(C36H59O3N3F).  
 
Antibacterial and antifungal assays  
The antibacterial and antifungal activities of the 
synthesized compounds were determined using well 
diffusion method32 against different pathogenic 
bacterial strains such as Micrococcus luteus MTCC 
2470, Staphylococcus aureus MTCC 96, 
Staphylococcus aureus MLS-16 MTCC 2940, 
Bacillus subtilis MTCC 121, Escherichia coli MTCC 
739, Pseudomonas aeruginosa MTCC 2453 and 
Klebsiella planticola MTCC 530 along with different 
Candida strain such as Candida albicans MTCC 
3017. All these bacterial and fungal strains were 
procured from the Microbial Type Culture Collection 
and Gene Bank (MTCC), CSIR-Institute of Microbial 
Technology, Chandigarh, India. The pathogenic 
reference strains were seeded on the surface of the 
media Petri plates, containing Muller-Hinton agar 
with 0.1 mL of previously prepared microbial 
suspensions individually containing 1.5 × 108 cfu ml-1 
(equal to 0.5 McFarland standard). Wells of 6.0 mm 
diameter were prepared in the media plates using a 
cork borer and the synthesized compounds dissolved 
in 10% DMSO at a dose range of 125 - 0.97 µg were 
added in each well under sterile conditions in a 
laminar air flow chamber. Standard antibiotic 
solutions of ciprofloxacin (bacterial strains) and 
miconazole (Candida strains) at a dose range of 125 - 
0.97 µg well-1, served as positive controls, while the 
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well containing DMSO served as negative control. 
The plates were incubated for 24 h at 30°C and the 
well containing the least concentration showing the 
inhibition zone is considered as the minimum 
inhibitory concentration. All experiments were carried 
out in duplicates and mean values are represented. 
 
Minimum bactericidal concentration 
Minimum bactericidal concentration assay 
(NCCLS, 2000) were performed in sterile 2.0 mL 
microfuge tubes against Bacillus subtilis MTCC 121 
which were procured from the Microbial Type 
Culture Collection (MTCC), CSIR-Institute of 
Microbial Technology, Chandigarh, India. The 
pathogenic Bacillus subtilis strain was cultured 
overnight in Mueller Hinton broth. Serial dilutions of 
synthesized compounds were prepared in Mueller 
Hinton broth with different concentrations ranging 
from 0 to150 µg/mL. To the serially diluted the 
synthesized derivatives, 100 µL of overnight cultured 
bacterial suspension was added to reach a final 
concentration of 1.5 × 108 cfu ml-1 (equal to 0.5 
McFarland) and incubated at 37ºC for 24 h. After 24 h 
of incubation, the minimum bactericidal concentration 
(MBC) was determined by sampling 10 µL of 
suspension from the tubes onto Mueller Hinton agar 
plates and were incubated for 24 h at 37ºC to observe 
the growth of test organisms. MBC is the lowest 
concentration of synthesized derivatives required to 
kill a particular bacterium. All the experiments were 
carried out in duplicates.  
 
Biofilm inhibition assay 
The test compounds were screened in sterile 96 
well polystyrene microtiter plates using the modified 
biofilm inhibition assay34, against a panel of 
pathogenic bacterial strains including Staphylococcus 
aureus MTCC 196, Staphylococcus aureus MLS-16 
MTCC 2940, Micrococcus luteus MTCC 2470 and 
Klebsiella planticola MTCC 530, which were 
cultured overnight in tryptone soy broth 
(supplemented with 0.5% glucose). The test 
compounds of predetermined concentrations ranging 
from 0 to 250 µg/mL were mixed with the bacterial 
suspensions having an initial inoculum concentration 
of 5 × 105 CFU/mL. Aliquots of 100 µL were 
distributed in each well and then incubated at 37ºC for 
24 h under static conditions. The medium was then 
discarded and washed with phosphate buffered saline 
to remove the non-adherent bacteria. Each well of the 
microtiter plate was stained with 100 µL of 0.1% 
crystal violet solution followed by 30 min incubation at 
room temperature. Later the crystal violet solution from 
the plates was discarded, thoroughly washed with 
distilled water for 3 to 4 times and air dried at room 
temperature. The crystal violet stained biofilm was 
solubilised in 95% ethanol (100 µL) and the 
absorbance was recorded at 540 nm using TRIAD 
multimode reader (Dynex Technologies, Inc, Chantilly, 
VA, USA). Blank wells were employed as background 
check. The inhibition data were interpreted from the 
dose-response curves, where IC50 value is defined as 
the concentration of inhibitor required to inhibit 50% of 
biofilm formation under the above assay conditions. 
All the experiments were carried out in triplicates and 
the values are indicated as mean ± S.D. 
 
Conclusions 
In conclusion, in the present study a series of ethyl 
1-ethyl-6-fluoro-7-(4-alkylpiperazin-1-yl)-4-oxo-1,4-
dihydroquinoline-3-carboxylate derivatives were 
synthesized. All the newly prepared compounds were 
evaluated for their antimicrobial activities. Most of the 
compounds showed significant antimicrobial activities. 
Compound 8a having hexyl alkyl chain not only 
exhibited potent antimicrobial activity against the 
selective strains but also it was proved to be potent for 
antifungal activity. Compounds 8b (heptyl chain 
derivative) and 8c (nonyl chain derivative) also showed 
promising antimicrobial activities. These kinds of 
compounds would represent a promising class of 
antimicrobial agents that deserves further investigation 
and derivatization. 
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